Expression of FOXP3 and GATA3 Transcription Factors Among Bronchial Asthmatics in Northern Population

  • Rashmi Pandey
  • Ved PrakashEmail author
Original Research Article


Asthma is a common chronic airways inflammatory disorder in which the expression of genes for the transcription factors FoxP3 and GATA3 plays crucial roles in activation of specific T cells population and pathogenesis of asthma. Recent data have shown that Hb, Eosinophils, total leucocytes count (TLC), absolute eosinophil count (AEC), and IgE, may be involved in adversely influencing the status of several chronic diseases including asthma. In this communication, we have carried out a case control study in order to evaluate the expression of FoxP3, GATA-3 genes in 80 bronchial asthmatic patients using real time polymerase chain reaction technique, and also to analyse and compare the values of Hb, TLC, AEC, and IgE in asthmatics with 80 control subjects. The numbers of eosinophils and total leucocytes and the level of serum IgE were higher in asthmatics compared to healthy subjects. The relative expressions of FoxP3 and GATA-3 genes in control versus asthmatics were 12.42 ± 1.413 versus 5.79 ± 0.260 (P value = < 0.0001) and 4.731 ± 0.350 versus 8.415 ± 0.359 (P value = 0.0043), respectively. The asthmatics displayed comparatively decreased level of FoxP3 expression and higher level of GATA-3 expression. There was a positive and significant correlation between the level of IgE and expression of GATA-3 in asthmatics. Relatively lower level of FoxP3 mRNA expression in bronchial asthmatics may be linked with the sustained inflammatory process and decreased immune tolerance by asthmatics. A positive correlation of GATA-3 expression with the increase in IgE level shows it to be a characteristic of asthma. However, extensive work is required to delineate the targets involved in the pathogenesis of asthma for adequate therapeutic interventions.


IgE Asthma FoxP3 GATA-3 Gene expression 


Authors’ Contribution

RP designed and executed the experiments, analysed the data and wrote the manuscript. VP developed the hypothesis, provided clinical samples, generated facilities and funding acquisition and edited the manuscript.


This research was funded by the UPCST-Lucknow, India (Grant No. CST/SERPD/D-290).

Compliance with Ethical Standards

Conflict of interest

The authors declare no conflict of interests.


  1. 1.
    National Institutes of Health; National Heart, Lung and Blood Institute Global Initiative for Asthma; Global strategy for asthma management and prevention. Washington, DC: National Institutes of Health; National Heart, Lung and Blood Institute, 2003 Updated 2004. Available at NIH publication No. 02-3659, 2009.
  2. 2.
    Pandey R, Sharma B. Therapeutic applications of antiasthmatics, consequences and remedies. EC Pharmacol Toxicol. 2018;6(7):580–9.Google Scholar
  3. 3.
    Kupczyk M. Long-term deterioration of lung function in asthmatic outpatients. Respiration. 2004;71:233–40.CrossRefGoogle Scholar
  4. 4.
    Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161:1720–45.CrossRefGoogle Scholar
  5. 5.
    Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov. 2009;8:645–60.CrossRefGoogle Scholar
  6. 6.
    Pyzik M, Piccirillo CA. TGF-beta1 modulates FoxP3 expression and regulatory activity in distinct CD41 T cell subsets. J Leukoc Biol. 2007;82:335–46.CrossRefGoogle Scholar
  7. 7.
    Trzonkowski P, Szmit E, Myœliwska J, Myœliwski A. CD41CD251 T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans—impact of immunosenescence. Clin Immunol. 2006;119:307–16.CrossRefGoogle Scholar
  8. 8.
    Seroogy CM, Gern JE. The role of T regulatory cells in asthma. J Allergy Clin Immunol. 2005;116:996–9.CrossRefGoogle Scholar
  9. 9.
    Klunker S, Chong MM, Mantel PY. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J Exp Med. 2009;206:2701–15.CrossRefGoogle Scholar
  10. 10.
    Moorman JE, Rudd RA, Johnson CA. National surveillance for asthma–United States, 1980–2004. MMWR Surveill Summ. 2007;56:1–54.PubMedGoogle Scholar
  11. 11.
    Gregg R, Smith CM, Clark FJ. The number of human peripheral blood CD4+ CD25high regulatory T cells increases with age. Clin Exp Immunol. 2005;140:540–6.CrossRefGoogle Scholar
  12. 12.
    Knudson R, Slavin R, Lebowitz M, Burrows B. The maximal expiratory flow-volume curve. Normal standards, variability, and effects of age. Am Rev Respir Dis. 1976;113:587–600.PubMedGoogle Scholar
  13. 13.
    Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol. 2008;121:560–70.CrossRefGoogle Scholar
  14. 14.
    Robinson DS. The role of the T cell in asthma. J Allergy Clin Immunol. 2010;126(6):1081–91.CrossRefGoogle Scholar
  15. 15.
    Martinis M, Benedetto MC, Mengoli LP, Ginaldi L. Senile osteoporosis: is it an immune-mediated disease? Inflamm Res. 2006;55:399–404.CrossRefGoogle Scholar
  16. 16.
    OShea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4 + T cells. Science. 2010;327:1098–102.CrossRefGoogle Scholar
  17. 17.
    Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445–89.CrossRefGoogle Scholar
  18. 18.
    Mantel PY, Kuipers H, Boyman O. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol. 2007;5:2847–61.CrossRefGoogle Scholar
  19. 19.
    Lin Y-L, Shieh C-C, Wang J-Y. The functional insufficiency of human CD41 CD25 high T-regulatory cells in allergic asthma is subjected to TNF-a modulation. Allergy. 2008;63:67–74.CrossRefGoogle Scholar

Copyright information

© Association of Clinical Biochemists of India 2019

Authors and Affiliations

  1. 1.Departments of Pulmonary and Critical Care MedicineKGMULucknowIndia

Personalised recommendations